drug

glycopyrronium tosylate

Marketedupdated 2mo ago

by $DERM Journey Medical Corp

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 17, 2028

~2.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Feb 28, 2033formulationUS 10004717
Feb 28, 2033formulationUS 10543192
Feb 28, 2033compositionUS 10548875
Feb 28, 2033formulationUS 8859610
Feb 28, 2033method-of-use (U-2398)US 9259414
Jul 18, 2030formulationUS 97441054.0y
Dec 10, 2029formulationUS 86181603.4y
Oct 17, 2028formulationUS 100522672.3y

🐶 often sniffed alongside

top 1

tagApproval2 co-mentions · 1 sources

Trials studying glycopyrronium tosylate

phase2Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosiswithdrawn